Skip to content

Impact of Whey Protein Supplementation on Body Weight and Metabolic Parameters of Bariatric Patients

Impact of Whey Protein Supplementation on Body Composition, Energy Expenditure and Biochemical Parameters of Patients Submitted to Bariatric Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04510389
Enrollment
40
Registered
2020-08-12
Start date
2019-03-01
Completion date
2023-02-14
Last updated
2023-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bariatric Surgery, Sarcopenia

Keywords

obesity, sarcopenia, bariatric surgery, protein

Brief summary

Obesity is a metabolic disorder, characterized by an increase in the body's fat mass, which will reflect an increase in total body weight. In Brazil, overweight accounts for 53.8% of the population, and of these 18.9% are obese. Surgical treatment is currently the most successful method for weight loss in patients with Grade III obesity and reduced associated morbidities. The general objective is to evaluate genetic, inflammatory, and dietary factors that would influence weight loss and the appearance of protein deficiency or sarcopenia in patients undergoing bariatric surgery and to evaluate the effects of protein supplementation for 8 weeks after the 18th postoperative month in the parameters evaluated. The study has a randomized, placebo-controlled, double-masked model. The patients will be selected in two bariatric surgery services accredited by the Brazilian Health Unic System (SUS) in the city of Belo Horizonte, Brazil. The project has already been approved by the Brazilian Ethics committee CONEP/UFMG by nº. 75415317.8.0000.5149. Patients of both sexes over 20 years of age will be included, attending the hospitals of the project with regular follow-up in the postoperative period. Data on anthropometry, body composition, muscle strength, energy expenditure, and inflammatory profile will be collected. The data will be correlated with the evaluation of the presence of genetic polymorphisms.

Detailed description

Specific objectives: It is also objective to evaluate: * To observe the food consumption between 18 and 24 months of surgery with respect to protein and caloric intake; * Evolution of weight loss, lean mass, fat mass and metabolic rate before and after supplementation with WP or placebo; * Changes in protein status (assessed by muscle strength and serum levels of total protein, albumin, prealbumin, ferritin, hemoglobin) before and after supplementation with WP or placebo * The inflammatory blood profile (assessed by cytokine levels and before and after supplementation with WP or placebo). * The influence of the rS9939609 polymorphism of the FTO gene on the nutritional status, biochemical and inflammatory parameters in the postoperative (after 18 months) of surgery;

Interventions

DIETARY_SUPPLEMENTMaltodextrin

Bariatric patients with or without sarcopenia receiving maltodextrin

DIETARY_SUPPLEMENTWhey

Bariatric patients with or without sarcopenia receiving whey protein

Sponsors

Federal University of Minas Gerais
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

Patient will receive indistinguishable sachets containing 30g of maltodextrin (placebo) or 30g whey protein. The sachets codification and patient allocation will be prepared by an individual without any contact with patients or the team which will follow patients

Intervention model description

randomized

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients of both sexes over 20 years of age * Patients with regular follow-up in the postoperative period.

Exclusion criteria

* Patients with debilitating chronic diseases * Severe vomiting * Submitted to other surgical procedures before 18 months of surgery * Patient with prostheses * Use or introduction of drugs immunosuppressants or affecting metabolism

Design outcomes

Primary

MeasureTime frameDescription
Body Weight variation8th weekmeasured in scale presented in kg
Muscle mass8th weekmeasure by portable US

Secondary

MeasureTime frameDescription
Muscle mass4th weekmeasure by portable US
Body Weight variation4th weekmeasured in scale presented in kg
Serum albumin4th weekmeasured in serum in g/dL
SNP (FTO) detection1st weekmeasure by polymerase chain reaction (PCR) in present or absence of A and T allele
Resting metabolic rate4th weekmeasured by indirect calorimetry in kcal/kg/day

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026